Article Text

PDF

Oesophageal free papers
OC-086 Surgery alone vs chemoradiotherapy followed by surgery for stage I and II oesophageal cancer: final analysis of a randomised controlled phase III trial—FFCD 9901
  1. W B Robb1,
  2. C Mariette1,2,3,4,
  3. L Dahan2,5,
  4. E Maillard2,6,
  5. F Mornex2,7,
  6. B Meunier2,8,
  7. V Boige2,9,
  8. C Genet2,10,
  9. D Pezet2,11,
  10. P A Thomas2,12,
  11. J P Triboulet1,2,3
  1. 1Department of surgical oncology, Lille University Hospital, Lille, France
  2. 2Fédération Française de Cancérologie Digestive, Dijon, France
  3. 3Université Lille-Nord de France, France
  4. 4Inserm, UMR837, Team 5 “Mucins, Epithelial differentiation and carcinogenesis” JPARC, Lille, France
  5. 5Department of Oncology, La Timone, University Hospital, Marseille, France
  6. 6Department of Biostatistics, Fédération Française de Cancérologie Digestive, Dijon, France
  7. 7Department of Radiotherapy, Pierre-Bénite Hospital, Lyon, France
  8. 8Department of Digestive Surgery, University Hospital, Rennes, France
  9. 9Department of Oncology, Institut Gustave Roussy, Villejuif, France
  10. 10Department of Gastroenterology, University Hospital, Limoges, France
  11. 11Department of Surgery, University Hospital, Clermont-Ferrand, France
  12. 12Department of Thoracic Surgery, Hôpital Nord, Marseille, France

Abstract

Introduction Resection remains the best treatment for local control of oesophageal carcinoma (OC), but local recurrence, distant metastasis and poor survival remain an issue after surgery. Often investigated in locally advanced OC, the impact of neoadjuvant chemoradiotherapy (NCRT) is unknown in patients with stage I or II OC. The aim of this multicentre randomised controlled phase III trial was to assess whether NCRT improves outcomes for patients with stage I or II OC.

Methods 195 patients were randomly assigned to surgery alone (S group, n=98) or to NCRT group (NCRT group, n=97; 45Gy given in 25 fractions over 5 weeks with two courses of concomitant chemotherapy by 5-Fluorouracil 800 mg/m2 on days 1–4 and cisplatin 75 mg/m2 on day 1 or 2). The primary endpoint was overall survival. Secondary endpoints were progression free survival, postoperative morbidity and 30-day mortality, R0 resection rate and prognostic factor identification. Analysis was done by intention to treat.

Results Patient and tumour characteristics were well-balanced between the two groups. Patients were preoperatively staged I in 18%, IIA in 49.7%, IIB in 31.8%, unknown in 0.5%. Postoperative morbidity and 30-day mortality rates were 49.5% vs 43.9% (p=0.17) and 1.1% vs 7.3% (p=0.054) in the S group and NCRT group, respectively. After a median follow-up of 5.7 years, 106 deaths were observed. Median survivals were 43.8 vs 31.8 months, respectively (HR 0.92, 95% CI 0.63 to 1.34, p=0.66). The trial was stopped due to futility.

Conclusion Compared with surgery alone, NCRT with cisplatin and 5-Fluorouracil does not improve overall survival but enhances postoperative mortality for patients with stage I or II OC (Clinical Trial.gov identifier NCT 00047112).

Funding Funded by the French ministry of Health—Programme Hospitalier de Recherche Clinique 1999.

Competing interests None declared.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.